Working…
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered SARS-CoV-2.
Protect yourself and others from infection by washing your hands, wearing masks or using an alcohol based rub frequently and not touching your face.

CUReD:  CSIR Ushered Repurposed Drugs -  A website that provides information on CSIR Partnered Clinical Trials.

   Details of Tinospora cordifolia + Piper longum

Name of trial A Randomized, Open Label, Parallel Efficacy, Active Control, Multi-Centre Exploratory Drug Trial to Evaluate Efficacy and Safety of Ayurvedic formulation-2 (T. cordifolia + P. longum) as Adjunct Treatment to Standard of Care for the management of Mild to Moderate COVID-19 Patients
CSIR lab/s involved Clinical Trial Site/s

CSIR-Indian Institute of Integrative Medicine, Jammu

 

Medanta Institute of Education and Research, Gurgram

Noble hospital,153, Road, Magarpatta, Hadapsar, Pune, Maharashtra

Department of Medicine, King George Medical University, Lucknow-226003

TN Medical College & BYL Nair Hospital, Dr. AL Nair Road, Mumbai Central, Mumbai

 
Type of Drug Sanshamani Vati Plus: Each tablet to contain 300 mg Guduchi plus 75 mg Pippali,
Mechanism of Action & Scientific rationale for Covid-19

The Sanshamani Vati is dried aqueous extract of Tinospora cordifoila (TC) indicated in VKJ and immunocompromised conditions. Its immune modulating function has been effectively used HIV and chikungunya. The advisory by the AYUSH Ministry for COVID-19 has also recommended Sanshamani Vati [equivalent of 200 ml decoction of Tinospora cordifoila and 4 grams Piper longum powder / day orally] for improving immunity. Samshamani Vati Plus is a formulation made up of aqueous extract of Tinospora cordifolia (TC) and fine powder of Piper longum (PL). This combination is specific to VKSJ and is mentioned in Ashtanga Hrudaya. This has been selected as therapeutic intervention considering its specificity to the clinical picture of COVID-19 and the known immune-enhancing effect of TC and effects of PL in respiratory system. Samshamani Vati will be given 500 mg thrice daily with warm water for 2-3 weeks.
Combinations therapy or monotherapy As Adjunct Treatment to Standard of Care
Trial design

Health Condition / Problems Studied

 

 Inclusion criteria
  1. Typical clinical presentation of acute onset febrile illness with cough and a RT_PCR based laboratory confirmation test for COVID-19
  2. Patients of either sex, 20 to 69 years age
  3. Patients with mild to –moderate disease
  4. Patients must agree not to share medication
  5. Patients willing to participate and sign an informed consent

Number of trial sites       

Number of arms              

Number of patients         

04
02
140
Click here for End points (primary and secondary)
Status of the CSIR trial
Ongoing
Name & details of Clinical PI/s Dr. Sushilakatariya Medanta Institute of Education and Research, Gurugram
  Dr. Renuka Kulkarni-Munshi BYL Nair Hospital, Mumbai Central, Mumbai 400008
  Dr. D. Himanshu Reddy Department of Medicine, King George Medical University, Lucknow-226003
  Dr. Danish Menon Noble hospital,153, Road, Magarpatta, Hadapsar, Pune, Maharashtra

Back